420 with CNW — Georgia’s Expanded MMJ Program Triggers Influx of Patients

Georgia is seeing a sharp rise in medical cannabis registrations after a new state law broadened eligibility and introduced significant changes to the program.

The legislation expanded the list of medical conditions that qualify for treatment, authorized vaping as a permitted method of use for certain patients, and revised the state’s limits on THC content, among several other updates.

Active registrations increased from roughly 34,000 at the beginning of June to over 41,400, representing an increase of almost 22%. Since July 1, enrollment has climbed from 36,703 patients, marking growth of nearly 13% in three weeks.

Medical cannabis businesses say demand rose immediately after the law came into force, with customers arriving well before opening time on July 1. Industry leaders expect the program to continue expanding and predict that the number of registered patients could triple by the middle of 2027 as more people become eligible.

Among the most significant changes is the addition of lupus to the list of qualifying medical conditions. Previously, eligibility covered illnesses including Parkinson’s disease, cancer, multiple sclerosis, ALS, Alzheimer’s disease, chronic pain, autism spectrum disorder, and several other approved diagnoses. The law also removes the requirement that many conditions be classified as end-stage or severe before patients can participate.

The measure, introduced by Senator Matt Brass, also broadens the ways eligible adults may use medical cannabis. Patients aged 21 and older can now legally use vaporized products, while smoking remains prohibited. According to experts, inhaled cannabis products provide faster symptom relief as they take effect almost immediately, unlike oil-based alternatives that must pass through the digestive system and can require 30 minutes or longer before producing results.

In addition, the legislation replaces the previous 5% THC potency restriction with a possession limit allowing patients to hold up to 12,000 mg of THC.

When signing the bill in May, Gov. Brian Kemp said the reforms provide important benefits for patients without changing Georgia’s overall approach to cannabis policy. He reiterated his opposition to recreational legalization but acknowledged that medical cannabis can offer meaningful relief for people who might otherwise depend on stronger opioid medications.

The law further updates statutory language by replacing the term “low THC oil” with “medical marijuana” and assigns the Georgia Access to Medical Cannabis Commission responsibility for expanding public education efforts about the program, its approved products, and their potential benefits for eligible patients.

Legal marijuana companies like Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) and others around the country will be glad the law in Georgia has allowed more patients to gain legal access to medicinal marijuana products.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Study Shows Restless Legs Syndrome Patients Benefit from Medical Marijuana

A new study suggests that marijuana-based treatment may provide lasting relief for people living with restless legs syndrome (RLS).

RLS causes an overwhelming urge to move the legs and disrupts sleep. The disorder affects an estimated 7 to 12 percent of adults in North America and Europe and is more frequent among those with multiple sclerosis.

For many years, dopamine agonists have been considered the primary therapy for RLS. More recently, however, research has shifted toward gabapentinoids as a preferred option. Since cannabinoids and gabapentinoids influence similar biological pathways involving certain amino acids linked to the condition, researchers wanted to determine whether cannabis compounds could also ease symptoms.

The open-label study enrolled adults with long-term RLS whose symptoms had persisted despite existing therapies. Most of the participants also had multiple sclerosis.

At the beginning of the trial, participants were prescribed an oral spray containing tetrahydrocannabinol (THC) and cannabidiol (CBD). They were instructed to take the medication in the evening shortly before symptoms typically emerged.

During the first month, doses were adjusted individually to identify the amount that delivered the greatest benefit. Once an effective dose was established, treatment remained unchanged for the rest of the study period.

Researchers monitored progress using established questionnaires and wrist-based sleep tracking devices known as actigraphy monitors. The primary outcome focused on symptom severity, measured with the International RLS rating scale. The team also evaluated sleep quality, daytime drowsiness, overall well-being, and participants’ ability to tolerate the treatment.

According to the findings, the cannabis formulation, containing 2.5 mg of CBD and 2.7 mg of THC, reduced the severity of RLS in patients with multiple sclerosis as well as those with idiopathic forms of the condition.

The study, which involved 18 participants, found noticeable improvements after one month and again after three months of treatment. Among those who remained on therapy, the benefits were still present one year later. Researchers reported that 67% of patients who continued treatment for a year maintained meaningful symptom improvement.

Although cannabis has already demonstrated benefits in easing muscle spasms and related neurological conditions, its potential use for RLS stands out because no U.S. states specifically identify RLS as a qualifying condition for medical marijuana programs.

The study adds to growing interest in alternative therapies that may eventually reduce dependence on dopamine agonists and expand treatment choices for people with restless legs syndrome.

Marijuana companies like Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) are unlikely to be surprised by the findings of this study since the full therapeutic potential of marijuana and its compounds is yet to be fully scientifically documented.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Nebraska Allows Grower to Start Medical Cannabis Cultivation

Nebraska cannabis regulators have approved the first licensed cultivation company to begin growing cannabis nearly 19 months after state voters endorsed legalization for medical use.

During a meeting on Monday, members of the Nebraska Medical Cannabis Commission unanimously confirmed that MahaMota Cultivation Company had successfully completed its inspection process, clearing the way for the company to grow the state’s first legal medical cannabis crop.

The commission has spent much of the past year developing rules and oversight procedures after holding its initial meetings in June of last year. While officials have suggested the first crop could be harvested by autumn, they have not changed their projected timeline that places the first retail sales in spring 2027.

Progress has not been uniform among the state’s approved growers. Nebraska law tightly restricts participation in the sector, allowing only four cultivation licenses, four manufacturing permits, and 12 dispensary licenses statewide.

The state’s medical cannabis framework also imposes strict limits on products available to patients. Possession of unprocessed marijuana is still prohibited, and the law also does not permit edible products or cannabis intended for smoking or vaping.

One licensed cultivator, KRL Med, continues to face setbacks linked to a zoning disagreement in Washington County. The company, owned by former state senator Kent Rogert, was informed shortly before a planned inspection in May that its proposed marijuana operation could not qualify under an agricultural exemption. However, hemp production would be eligible.

The dispute has resulted in a stop-work order that prevents the company from completing construction of a greenhouse and limits access to the site. Despite the ongoing conflict, regulators voted unanimously to extend KRL Med’s license for another six months.

The remaining licensed cultivators are also encountering obstacles. Meadowlark Medicinals postponed its inspection for undisclosed reasons. Meanwhile, Midwest Cultivator Group received approval to move its planned operation from Omaha to Gretna due to local zoning standards. Gretna officials have already granted the company a conditional-use license.

Commissioners also voted 3-1 to begin accepting applications for cannabis manufacturing licenses. Officials expect to gather submissions during the next month before assessing associated fees.

Several regulatory issues remain unresolved. Permanent rules still require approval from state AG Mike Hilgers, a longtime opponent of medical marijuana. Governor Jim Pillen must also sign off before the regulations can take effect without a sunset provision. The commission is scheduled to meet again on July 20.

While the Nebraska medical marijuana program is very limited in its scope, industry actors like Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) operating in other legal markets will be pleased that modest steps have been taken to give Nebraskans a legal way to access medical marijuana products within the state.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Federal Cannabis Trafficking Cases Dwindle Amid State-Level Legalization

Federal prosecutions tied to marijuana trafficking have dropped to their lowest level on record, reflecting a 95% decline that has unfolded over more than a decade, according to newly released figures from the U.S. Sentencing Commission.

The commission’s data shows that fewer than 400 individuals faced federal marijuana trafficking charges in 2025. That marks the smallest annual total ever recorded and highlights the changing landscape of cannabis enforcement across the country. Marijuana-related cases accounted for just 2% of all federal drug trafficking prosecutions during the year.

The contrast with earlier years is striking. In 2012, federal courts sentenced close to 7,000 people for offenses involving marijuana trafficking. That same year marked a turning point in U.S. cannabis policy when voters in Washington and Colorado approved the nation’s first legal frameworks for adult recreational marijuana sales.

Since then, federal prosecution numbers have steadily moved downward. By 2015, the annual total had fallen below 4,000 cases, and by 2019 it had dropped to fewer than 1,000.

The reduction in federal marijuana prosecutions mirrors a similar pattern seen at the U.S.-Mexico border. Government records indicate that border agents seized approximately 61,000 pounds of marijuana in 2023, the lowest amount reported in modern records. Compared with 2013 levels, that represents a decline of roughly 98% in cannabis seizure activity.

Observers say the figures reflect broader shifts in how marijuana is produced, distributed, and sold throughout the U.S. As more states establish regulated cannabis markets, demand for illicitly imported marijuana appears to have weakened, contributing to lower enforcement activity at both the border and the federal court level.

Paul Armentano, deputy director of NORML, noted that the statistics suggest that state-regulated cannabis programs are having a significant impact on illegal marijuana commerce. He argued that the growth of licensed markets has reduced the role of international suppliers while allowing federal authorities to direct attention and resources toward other criminal investigations that may present greater public safety concerns.

The sentencing data also offers a wider snapshot of federal criminal enforcement. Drug-related offenses continued to represent a substantial share of the federal caseload in 2025, accounting for nearly one-quarter of all prosecutions.

Among those cases, methamphetamine remained the dominant focus for federal authorities. Almost half of individuals prosecuted for federal drug crimes were involved in offenses connected to methamphetamine, making it the most common drug category in the federal system.

The wider marijuana industry, including major companies like Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF), will be happy that fewer people are now being prosecuted for marijuana-related offenses now that most of the country has legalized some form of the drug.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — TSA Starts Allowing Medical Cannabis Through Airports

Travelers moving through Orlando International Airport are responding to a recent change in Transportation Security Administration guidance that permits, in limited situations, medical cannabis to pass through airport security screening.

The adjustment represents a notable departure from earlier federal rules that treated marijuana as prohibited during airport screening processes. Officials, however, emphasize that authorization at the federal checkpoint does not override state or municipal regulations governing possession and use.

Several people interviewed by News 6 at the airport admitted they had not heard about the revised approach until recently.

One traveler said the information came as a surprise, adding that the adjustment could benefit people who rely on cannabis for health-related treatment. Another welcomed the development, describing it as a positive decision and arguing that people should have access to medications they legitimately require, regardless of the form those treatments take.

Earlier this year, the Trump administration took steps toward moving marijuana from its previous classification as a Schedule I substance to Schedule III, a category viewed as less restrictive. The move followed years of expanding legalization efforts nationwide, with dozens of states approving medical cannabis.

Despite the policy change, uncertainty remains among many travelers about what is actually permitted at airport checkpoints. Some passengers told News 6 they had little understanding of the rules, while others noted that public discussion surrounding the change has been limited.

The TSA has clarified that its officers are not actively looking for cannabis or narcotics during screenings. Instead, security personnel are tasked with identifying threats that could endanger aircraft or passengers. Supporters of the revised policy say that allowing officers to concentrate on aviation safety rather than small amounts of medical cannabis makes sense.

Questions still remain over how officials would determine whether a traveler possesses a valid medical cannabis authorization. Procedures for verifying eligibility have not been clearly outlined.

In situations where law enforcement is summoned to a checkpoint, the Orlando Police Department noted that officers would review each case individually and apply relevant laws as necessary.

Under city regulations in Orlando, individuals without authorization for medical cannabis may receive a $100 citation if found carrying less than 20 grams.

Despite the new guidance, confusion persists among travelers, with some describing marijuana regulations in Florida as unclear and inconsistently understood. Meanwhile, TSA officials continue reminding passengers that local and state regulations remain in effect, even as federal policies evolve.

Companies like Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) operating in Florida and other states will continue to monitor this evolving situation at airports and possibly offer guidance to their customers as more information becomes available.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Georgia Governor Signs Bill Expanding Access to Medical Marijuana

Georgia Governor Brian Kemp has approved legislation that broadens access to the state’s medical cannabis program, introducing several changes aimed at expanding treatment options for eligible patients while maintaining restrictions on recreational marijuana. The measure, Senate Bill 220, adds new qualifying medical conditions, revised rules on THC limits, and expanded methods for how patients may use cannabis products.

Under the updated law, individuals diagnosed with lupus will now qualify for medical cannabis treatment in Georgia. The move widens eligibility under a system that already permits access for patients coping with conditions such as cancer, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), autism spectrum disorder, chronic pain, and several other serious illnesses.

The legislation, sponsored by Senator Matt Brass, also eases restrictions that previously prevented some patients from participating unless their condition had reached a severe or terminal stage.

Another major adjustment involves the way patients can consume medical cannabis. Before the passage of the bill, approved products were limited to oils, capsules, tinctures, topical treatments, transdermal patches, and lozenges. With the new changes in place, patients aged 21 and older will now be permitted to use vaporized cannabis products. Smoking marijuana, however, remains prohibited for all patients.

The law, formally titled the Putting Georgia’s Patients First Act, also reshapes the state’s approach to THC restrictions. Georgia previously enforced a cap limiting products to 5% THC concentration. The revised framework instead allows registered patients to possess up to 12,000 mg of THC at one time.

The legislation also updates statutory language by replacing references to “low THC oil” with the broader term “medical cannabis.”

In addition, the Georgia Access to Medical Cannabis Commission will take on expanded responsibilities related to public education. The agency will now be tasked with increasing awareness about medical cannabis, including its potential uses and benefits for eligible patients. Outreach efforts will target residents, healthcare professionals, and law enforcement agencies through educational materials and public engagement campaigns.

In remarks released alongside the signing, Kemp said that while the revisions are important for patients relying on medical cannabis, the law does not dramatically alter Georgia’s position compared with other states. He noted that the legislation gained broad backing in both chambers of the state legislature.

At the same time, the governor acknowledged lingering concerns surrounding recreational marijuana legalization. Kemp said he shares the reservations expressed by critics who fear medical programs could eventually lead to wider recreational use. He pointed to examples of states that, in his view, have reconsidered broad cannabis legalization after implementation.

The latest reform follows broader discussions around cannabis policy in Georgia. Last year, House lawmakers established a Blue-Ribbon Study Committee to review the state’s medical marijuana and hemp laws. Separately, legislators have explored proposals focused on researching the possible therapeutic applications of psychedelics.

Marijuana companies across the country, such as Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF), will be pleased that access to medical marijuana has been broadened in Georgia and thousands of patients who had previously been locked out can now use the products they need.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — How Top Brands, Politicians Celebrated Marijuana’s 4/20 Holiday

April 20, widely known as 4/20, has become an informal holiday associated with cannabis use. As public attitudes continue to shift and legalization spreads across the U.S., more public officials and companies are openly acknowledging the day. This year, messages shared online reflected a mix of celebration, policy advocacy, and public safety reminders.

Lawmakers used the occasion to highlight economic and legislative arguments tied to marijuana policy. Pennsylvania Governor Josh Shapiro pointed to the financial impact of prohibition in his state, noting that residents are traveling elsewhere to purchase cannabis, taking significant tax revenue with them. He urged lawmakers to act and move legalization legislation forward.

California Governor Gavin Newsom reflected on a decade since voters approved legalization in the state. He emphasized steps taken to address past inequities and regulate the industry more effectively, while also signaling that further improvements are underway.

In Kentucky, Governor Andy Beshear focused on the economic and medical benefits of cannabis, citing job creation and business growth tied to recent policy changes.

Colorado Governor Jared Polis took a different approach, reminding residents to celebrate responsibly and avoid impaired driving. Similar concerns were echoed by Pennsylvania Lieutenant Governor Austin Davis, who argued that delays in legalization continue to cost the state substantial annual revenue.

Democratic groups in several states reiterated support for legalization, with Wisconsin Democrats linking the issue to electoral outcomes and Wyoming Democrats contrasting their stance with Republican opposition.

At the federal level, lawmakers used 4/20 to push for sweeping changes. Senator Cory Booker called attention to ongoing disparities, noting that while cannabis is legally sold in many areas, people with past convictions still face barriers to employment and housing. He advocated for expunging records and establishing a national regulatory system.

Other members of Congress echoed similar themes. Senator John Hickenlooper highlighted Colorado’s approach as a model for potential nationwide legalization. Senator Tina Smith argued that federal laws have not kept pace with state-level changes, while Representative Dina Titus promoted legislation aimed at easing restrictions on cannabis research.

Calls for criminal justice reform were also prominent. Representative Ilhan Omar urged the passage of legislation to decriminalize marijuana and clear past convictions. Representative Jerry Nadler emphasized the need to address the uneven impact of past drug policies, particularly on marginalized communities.

Meanwhile, government agencies focused on public safety. The National Highway Traffic Safety Administration reminded the public that impaired driving remains illegal nationwide. Cannabis state regulators issued similar warnings, encouraging individuals to plan ahead and avoid getting behind the wheel after consuming cannabis.

Major brands, meanwhile, leaned into the day with marketing campaigns and themed promotions. Companies across the food, beverage, and retail sectors used social media to connect with audiences, often incorporating lighthearted references to cannabis culture. Some opted for subtle nods, while others took a more direct approach.

Ben & Jerry’s, for instance, tied its 4/20 messaging to criminal justice reform, calling attention to racial disparities in marijuana arrests and urging federal legalization that addresses those inequities. The company encouraged its audience to view the day as both a cultural moment and an opportunity for advocacy.

For entities like Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF), the day offered an opportunity to reflect on how far these businesses have come and on what more they need to do to not only survive but also thrive in the evolving market.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Alabama to Finally Launch its Medical Marijuana Program

Alabama is preparing to roll out its long-awaited medical cannabis program, with the first dispensary set to open in the state capital next month.

Callie’s Apothecary in Montgomery is scheduled to begin serving patients on May 4, marking a milestone for a system that has faced repeated setbacks. The shop is the first of nine dispensaries expected to be operating by the summer, according to updates shared during an April 9 meeting of the Alabama Medical Cannabis Commission.

Commission Chair Dr. Sam Blakemore said progress is ongoing but not yet complete. One additional license remains tied up, delaying the full rollout. He expressed hope that all 12 approved dispensaries would be functioning by the final quarter of the year.

So far, roughly 40 doctors have been cleared to recommend medical marijuana, and 66 patients have received official authorization cards.

The launch comes five years after the state legalized medical cannabis in 2021. What was initially expected to move forward quickly became entangled in legal challenges. Several companies that were denied licenses filed lawsuits, questioning how permits were distributed. Those disputes forced regulators to revisit their decisions multiple times, pushing the program’s debut far beyond its original timeline.

Even now, as the first sales approach, scrutiny of the commission continues. A recent audit highlighted a series of concerns, including issues with documentation practices, adherence to open meetings rules, and questions surrounding fee policies. The audit also pointed to an overpayment exceeding $204,000 to an external law firm.

In response, state legislators have introduced several proposals this session aimed at reshaping the commission’s structure and revising how its members are appointed.

The current framework permits up to five vertically integrated companies, each able to operate as many as five storefronts. In addition, the state may license 12 cultivators, four processing facilities, and four standalone dispensary operators, with each of those allowed up to three locations.

So far, regulators have issued licenses to four dispensary operators, four processors, and nine growers. The retail permits were finalized in December.

Advocacy groups say the launch is only one part of the challenge. The Alabama Cannabis Coalition is urging officials to begin a statewide education effort, arguing that many patients who qualify for treatment still do not understand how to access it legally.

Under state rules, patients must first register in an official database and obtain certification from an approved physician before they can purchase cannabis products. Despite these rules being in place for a while, advocates say public awareness remains limited.

Those desiring marijuana policy reform around the country will be pleased that concrete steps are now taking shape in Alabama and patients could soon access MMJ legally. Firms like Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) will be hoping that the program stabilizes and no further setbacks hinder its implementation.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — US Military Scraps Cannabis Restrictions, Bumps Up Recruitment Age Bracket

The United States Army has introduced new recruitment rules that expand eligibility, allowing older applicants to join. Under the updated policy, individuals up to 42 years old can now enlist in active duty, the Army Reserve, and the Army National Guard. This marks a notable shift from the previous age limit of 35.

Alongside the change in age requirements, the Army has revised its stance on applicants with minor cannabis-related convictions. Those with a single offense involving possession of cannabis or related items such as pipes or similar equipment are no longer automatically subject to additional hurdles. In the past, such cases required a formal waiver issued by Pentagon officials. Applicants also had to wait two years before becoming eligible and pass a drug screening.

Officials say the updates are part of a broader effort to strengthen recruitment, which has lagged in recent years. In 2022, the Army fell significantly short of its enlistment goals, missing its target by roughly a quarter. The new measures are intended to widen the pool of eligible candidates and address ongoing staffing challenges.

The decision to raise the age cap also aligns the Army more closely with other branches of the military, including the Air Force and the Navy, both of which have already adopted higher age limits.

Analysts have pointed out that older recruits often bring valuable qualities to the force. A 2023 study by the RAND Corporation suggested that individuals who enlist later in life tend to be more disciplined, motivated, and prepared for the demands of basic training. They may also bring prior work experience, particularly in technical fields, which can be useful in specialized military roles.

Army officials have acknowledged this shift in focus. Angela Chipman, who oversees personnel accessions, indicated that the service is increasingly interested in candidates with practical skills and professional experience. She noted that certain positions, especially those requiring advanced technical knowledge, could benefit from recruits who have already developed expertise outside the military.

These policy changes come at a time of heightened military activity overseas. The United States has recently deployed thousands of troops to the Middle East, including paratroopers and Marines, as part of ongoing operations linked to tensions involving Iran.

Meanwhile, lawmakers in Washington are considering additional funding requests tied to the conflict. A proposed package could add $200 billion to defense spending, which already exceeds the $900 billion budget.

The marijuana industry, including leading firms like Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF), is likely to welcome the easing of marijuana-linked restrictions on enlistment into the Army given the realities on the ground where drug policy has been reformed in more than half the country’s states to permit the use of marijuana either for medical or recreational purposes.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — IRS Clarifies Post-Rescheduling 280E MSO Marijuana Tax Arrears

Several large cannabis companies operating across multiple U.S. states collectively owe over $1.6 billion in unpaid federal taxes, according to information disclosed in recent corporate filings. The outstanding balances stem largely from disputes over Internal Revenue Code Section 280E, a provision that significantly limits the deductions marijuana businesses can claim.

Some marijuana companies have intentionally withheld payments in an attempt to preserve cash while challenging the rule. In a recent court filing tied to a marijuana tax dispute, IRS attorneys said the liabilities remain enforceable under existing law. They also say recent political developments surrounding federal cannabis policy do not alter obligations tied to earlier tax years.

Section 280E prevents businesses that handle substances listed under Schedule 1 or 2 of the Controlled Substances Act from writing off many routine operating costs on federal tax returns. The restriction has long weighed heavily on cannabis companies, many of which operate legally under state law but remain prohibited federally.

Over 40 operators have taken their arguments to the U.S. Tax Court, hoping to weaken or overturn the rule. Those efforts have so far not succeeded.

A New Mexico company, Top Organics, which sells products under the Ultra Health brand, is the latest to seek relief. Court records show the business filed a petition in December 2024 asking to claim deductions under Section 280E for tax years 2018 through 2020.

In an October filing, the company said the federal push to move marijuana to a less restrictive classification could transform the legal landscape. The filing pointed to an August 2023 recommendation from federal health regulators suggesting cannabis should move to Schedule 3.

However, marijuana remains listed under Schedule 1 for now, even after an executive order issued by President Trump on December 18 directing officials to begin the rescheduling process.

The DOJ has yet to carry out that directive. Until any formal change takes effect, the IRS maintains that prior tax obligations remain governed by the law in place when the income was earned.

In a March 6 court filing tied to the Top Organics dispute, IRS Acting Chief Attorney Kenneth Kies argued that courts have consistently upheld the constitutionality of Section 280E. Because marijuana was classified as a Schedule 1 substance during the years cited in the case, he wrote, the court must apply the rules that existed at that time.

The agency has taken the same position before, including in a memo issued in 2024.

Meanwhile, several large cannabis operators that began disputing their 280E liabilities in late 2023 have accumulated substantial uncertain tax positions. Trulieve Cannabis Corp. reported the largest exposure. The company amended returns dating back to 2019 and sought roughly $143 million in refunds based on its interpretation of the law. Its financial statements now list $630 million tied to the ongoing tax dispute.

Other companies have reported sizable amounts as well, including Curaleaf Holdings with $531.5 million, Verano Holdings at $378.26 million, and Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) with $171.4 million.

Many legal specialists remain skeptical that businesses will ultimately avoid the tax burden. Lawyer Henry Wykowski warned in a 2024 interview that betting on favorable court rulings is a dangerous approach. He said firms pursuing that path could face additional penalties exceeding 20% on top of unpaid taxes if their arguments fail.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com